If you were looking for penny stocks to watch, you stumbled along the right website. A few of the top stocks for Monday have already taken off big but today we’ll look at 2 penny stocks that could be on a much longer-term bull trend.
Penny Stock #1: Jaguar Health, Inc. (JAGX)
This healthcare penny stock has been in the news quite frequently. With this latest surge in biotechnology penny stocks that we’ve seen, Jaguar Health (JAGX – Get Report) is added to more watch lists each week. But why might this 33-cent stock be something for investors to watch?
Jaguar is a bit different from other biotech companies in that it is a commercial stage company. This is different from an investigational stage or clinical stage company. Jaguar focuses on developing gastrointestinal products at a global level.
Most recently the company met with the US FDA at the end of March. The meeting was to discuss its protocol for the planned trial to evaluate Mytesi®. This is a therapy used for the relief of diarrhea related to anticancer drug therapy.
The Mytesi ® product is already FDA approved for relief of noninfectious diarrhea in adults with HIB/AIDS who are on antiretroviral therapy. The share price of JAGX share has increased by as much as 3x compared to its levels on March 14.
Penny Stock #2: AVEO Pharmaceuticals, Inc. (AVEO)
Another biotechnology penny stock to watch, AVEO Pharmaceuticals (AVEO – Get Report) has had its fair share of troubles over previous months. But lately, the stock price trend has been aggressively more bullish. Similar to many other penny stocks that see dramatic decreases in price like AVEO did in January & February, the “ambulance chasing” lawyers have been out for blood. The Newsfeed is riddled with class action announcements.
What has AVEO done recently to warrant such a reversal in price? There are several rumors surfacing that AVEO will be acquired by AstraZeneca (AZN – Get Report) in Q2 2019.
That’s correct, according to Seeking Alpha, “representatives from various large investment banks believe AstraZeneca will soon make a move to acquire AVEO, which is nearing FDA approval for its Fotivda (tivozanib) kidney cancer medication.”
Sources cite that the price of the acquisition could be anywhere between $800 million to $1.2 billion USD. Though we can’t confirm these rumors to be 100% true, it has caused some excitement in the market for this penny stock.
